2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 438

High Multi-Biomarker Disease Activity Score Is Associated with High Risk of Radiographic Progression in Six Cohorts
Abstract Number: 1126

High Osteoprotegerin:RANKL Ratios in Synovial Fluid Correlate with the Presence of Calcium Pyrophosphate Crystals
Abstract Number: 1170

High Output Flow Cytometry Array Classifies Subjects with Uveitis Due to Behcet’s Disease and Sarcoidosis
Abstract Number: 692

High Plasma Factor XIII Transglutaminase Activity Inversely Correlates with SLE Disease Activity Yet Associates with Higher Carotid Artery IMT and Low CD14+CD16+ Monocyte Levels
Abstract Number: 2509

High Prevalence of Sarcopenia in Axial Spondyloarthropathy Cohort
Abstract Number: 1539

High Retention Rate and Sustained Responses with Secukinumab 150mg in Patients with Active Ankylosing Spondylitis: 3-Year Results from a Phase 3 Study
Abstract Number: 1662

High Type I Interferon Activity Is Associated with Active Class Ⅲ/Ⅳ Lupus Nephritis in European-American Lupus Patients Independent of dsDNA Antibodies
Abstract Number: 2366

High Uric Acid As a Risk Factor for Cardiovascular Diseases in Rheumatoid Arthritis Patients
Abstract Number: 1024

High-Throughput Proteomic Profiling Identifies Dysregulated Proteins in Neonatal-Onset Multisystem Inflammatory Disease (NOMID) That Respond to IL-1blocking Treatment
Abstract Number: 1680

Higher Baseline Monocyte Count Is Associated with More Extensive Skin Involvement and Higher Mortality in Systemic Sclerosis
Abstract Number: 1370

Higher Disease Activity in Current Smokers with Established RA: Is It Disease, Damage or Disability?
Abstract Number: 1416

Higher Expression of Type 1 Interferon in Synovitis of Patient with Undifferentiated Arthritis before They Met Rheumatoid Arthritis Criteria Compared to Established Rheumatoid Arthritis. a Retrospective Study with 14 Years of Follow-up
Abstract Number: 1075

Higher Frequencies of Lymphocytes Expressing the Natural Killer Group 2D Receptor and Cytotoxic Potential of NK Cells in Patients with Behcet Disease
Abstract Number: 1426

Higher Levels of Interleukin-6 As Well As Soluble Interleukin-6 Receptor Leads to Worse Clinical and Radiographic Prognosis in Rheumatoid Arthritis Patients Treated with Tocilizumab
Abstract Number: 990

Higher Omega-6 to Omega-3 Fatty Acid Ratio Is Associated with Increased Odds of Inflammatory Arthritis in a Health Fair Population Positive for Anti-Citrullinated Protein Antibodies (ACPA)

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].